PL2114873T3 - N-[3-Bromo-4-(3-[18F]fluoropropoksy)-benzylo]-guanidyna do obrazowania unerwienia serca - Google Patents

N-[3-Bromo-4-(3-[18F]fluoropropoksy)-benzylo]-guanidyna do obrazowania unerwienia serca

Info

Publication number
PL2114873T3
PL2114873T3 PL07869717T PL07869717T PL2114873T3 PL 2114873 T3 PL2114873 T3 PL 2114873T3 PL 07869717 T PL07869717 T PL 07869717T PL 07869717 T PL07869717 T PL 07869717T PL 2114873 T3 PL2114873 T3 PL 2114873T3
Authority
PL
Poland
Prior art keywords
fluoropropoxy
guanidine
bromo
benzyl
cardiac innervation
Prior art date
Application number
PL07869717T
Other languages
English (en)
Inventor
Ajay Purohit
Thomas D Harris
Heike S Radeke
Simon P Robinson
Ming Yu
David S Casebier
Michael T Azure
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Publication of PL2114873T3 publication Critical patent/PL2114873T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
PL07869717T 2006-12-26 2007-12-21 N-[3-Bromo-4-(3-[18F]fluoropropoksy)-benzylo]-guanidyna do obrazowania unerwienia serca PL2114873T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87721106P 2006-12-26 2006-12-26
PCT/US2007/088500 WO2008083056A2 (en) 2006-12-26 2007-12-21 Ligands for imaging cardiac innervation
EP07869717A EP2114873B1 (en) 2006-12-26 2007-12-21 N-[3-bromo-4-(3- [18f]fluoropropoxy)-benzyl]-guanidine for imaging cardiac innervation

Publications (1)

Publication Number Publication Date
PL2114873T3 true PL2114873T3 (pl) 2013-08-30

Family

ID=39307501

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07869717T PL2114873T3 (pl) 2006-12-26 2007-12-21 N-[3-Bromo-4-(3-[18F]fluoropropoksy)-benzylo]-guanidyna do obrazowania unerwienia serca

Country Status (21)

Country Link
US (4) US8491868B2 (pl)
EP (5) EP2474523B1 (pl)
JP (3) JP5656408B2 (pl)
KR (4) KR101718160B1 (pl)
CN (3) CN105622463B (pl)
AU (1) AU2007339954B2 (pl)
BR (1) BRPI0722082A8 (pl)
CA (2) CA2984226C (pl)
CO (1) CO6231002A2 (pl)
DK (3) DK2474523T3 (pl)
ES (3) ES2805286T3 (pl)
HK (1) HK1138260A1 (pl)
IL (3) IL199563A (pl)
MX (2) MX367292B (pl)
PL (1) PL2114873T3 (pl)
PT (1) PT2114873E (pl)
RU (1) RU2506256C2 (pl)
SG (1) SG177918A1 (pl)
TW (2) TWI549692B (pl)
WO (1) WO2008083056A2 (pl)
ZA (1) ZA200904828B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
PT2114873E (pt) 2006-12-26 2013-05-06 Lantheus Medical Imaging Inc Ligandos para imagiologia de inervação cardíaca
KR20180055933A (ko) 2010-02-08 2018-05-25 랜티우스 메디컬 이메징, 인크. 조영제 및 이의 중간체를 합성하는 방법 및 장치
MX367382B (es) * 2010-05-11 2019-08-19 Lantheus Medical Imaging Inc Composiciones, metodos y sistemas para la sintesis y el uso de agentes trazadores.
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
MX2012013255A (es) 2010-05-14 2013-02-27 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
KR20190015765A (ko) * 2011-09-09 2019-02-14 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
CN109125745B (zh) 2012-04-10 2022-07-26 蓝瑟斯医学影像公司 放射性药物合成方法
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2014052454A1 (en) * 2012-09-25 2014-04-03 The Regents Of The University Of Michigan Imaging agents
US20150366523A1 (en) 2013-01-24 2015-12-24 Shlomo Ben-Haim Neuronal imaging and treatment
JP6470185B2 (ja) * 2013-01-24 2019-02-13 タイラートン インターナショナル ホールディングス インコーポレイテッドＴｙｌｅｒｔｏｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｈｏｌｄｉｎｇｓ Ｉｎｃ． 身体構造イメージング
AU2014229201A1 (en) * 2013-03-11 2015-09-10 Tylerton International Inc. Modeling the autonomous nervous system and uses thereof
RU2016105108A (ru) 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. Ингибиторы факторов транскрипции и их применение
CN105705080B (zh) * 2013-09-08 2020-05-01 泰勒顿国际公司 用于诊断和治疗神经系统活动影响疾病模式的装置和方法
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015104672A2 (en) 2014-01-10 2015-07-16 Tylerton International Holdings Inc. Detection of scar and fibrous cardiac zones
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016016837A1 (en) 2014-07-30 2016-02-04 Navix International Limited Probe localization
EP3177147A4 (en) 2014-08-08 2018-01-24 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
CN107892651A (zh) * 2017-11-29 2018-04-10 陕西慧康生物科技有限责任公司 一种合成dl‑盐酸麻黄碱的方法
US20210379210A1 (en) * 2018-10-15 2021-12-09 Bristol-Myers Squibb Company Radioligands for imaging the lpa1 receptor
EP3682906A1 (en) 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter
CN109748825B (zh) * 2019-02-01 2022-02-18 原子高科股份有限公司 一种18f标记的胍甲基取代苯类似物及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
FR1010218A (fr) 1949-02-10 1952-06-09 American Cyanamid Co Perfectionnements aux sels de guanidine
GB1215255A (en) 1968-03-13 1970-12-09 Pfizer & Co C Halophenylalkylguanidine compounds
US4094881A (en) 1976-03-10 1978-06-13 Smithkline Corporation Process for preparing triazolethiols
US4275074A (en) 1979-03-09 1981-06-23 Graham J. Dobbie Catecholamine treatment of ocular hypertension
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4258188A (en) * 1980-02-04 1981-03-24 American Home Products Corporation 2-(1-Piperazinyl)-cycloheptimidazole derivatives
US4622217A (en) 1984-04-27 1986-11-11 The Regents Of The University Of Michigan I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
EP0288284A3 (en) * 1987-04-24 1990-07-25 King Faisal Specialist Hospital And Research Centre Method of producing iodine 124 and meta-iodobenzylguanidine containing iodine 124
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5674865A (en) * 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW279864B (pl) * 1993-02-19 1996-07-01 Janssen Pharmaceutica Nv
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5874573A (en) 1995-06-26 1999-02-23 Concat, Inc. Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
DK0944619T3 (da) 1996-11-27 2007-02-05 Bristol Myers Squibb Pharma Co Hidtil ukendte integrinreceptorantagonister
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CA2345710C (en) 1997-10-02 2008-12-30 The University Of Western Ontario Preparation of radiolabelled haloaromatics via polymer-bound intermediates
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
WO1999052861A1 (de) 1998-04-09 1999-10-21 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik
AU5671699A (en) 1998-08-14 2000-03-06 Smithkline Beecham Corporation Grp receptor ligands
JP2002532440A (ja) 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ビトロネクチン受容体拮抗剤薬剤
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
DE10114561A1 (de) 2001-03-24 2002-09-26 Wella Ag Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
AU2003298582A1 (en) 2002-09-17 2004-05-13 Isis Pharmaceuticals, Inc. Therapeutic guanidines
JP2007527389A (ja) 2003-06-30 2007-09-27 メルク　エンド　カムパニー　インコーポレーテッド 放射性カンナビノイド−１受容体修飾因子
AU2004294989B2 (en) 2003-12-01 2009-03-19 Ignasi Carrio Novel differential imaging method
US20060100225A1 (en) * 2004-03-23 2006-05-11 Xi Chen Heteroaryl guanidines; inhibitors of viral replication
US9388122B2 (en) * 2004-05-28 2016-07-12 Hamamatsu Photonics K.K. Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor
WO2006032705A2 (en) 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
US7534418B2 (en) * 2004-12-10 2009-05-19 The Regents Of The University Of Michigan Imaging agents
GB0512770D0 (en) 2005-06-23 2005-07-27 Hammersmith Imanet Ltd Imaging compounds
ATE509628T1 (de) * 2006-12-13 2011-06-15 Hoffmann La Roche Neue 2-imidazole als liganden für trace amine associated receptors (taar)
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
PT2114873E (pt) 2006-12-26 2013-05-06 Lantheus Medical Imaging Inc Ligandos para imagiologia de inervação cardíaca
WO2008082305A1 (en) 2006-12-28 2008-07-10 Raufoss Technology As Control arm
US7887784B2 (en) 2007-03-21 2011-02-15 University Of Montana 1-[(2′-substituted)-piperazin-1′ -yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents
AU2008312624B2 (en) 2007-10-18 2014-07-10 Boehringer Ingelheim International Gmbh Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein
WO2010015340A1 (en) 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0906274D0 (en) 2009-04-09 2009-05-20 Ge Healthcare Ltd Imaging the central nervous system
CN102458396B (zh) 2009-04-15 2017-05-10 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
JP5676600B2 (ja) 2009-07-08 2015-02-25 ランセウス メディカル イメージング， インコーポレイテッド 造影剤としてのｎ−アルコキシアミド抱合体
KR20180055933A (ko) 2010-02-08 2018-05-25 랜티우스 메디컬 이메징, 인크. 조영제 및 이의 중간체를 합성하는 방법 및 장치
MX367382B (es) 2010-05-11 2019-08-19 Lantheus Medical Imaging Inc Composiciones, metodos y sistemas para la sintesis y el uso de agentes trazadores.
KR20190015765A (ko) 2011-09-09 2019-02-14 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
EP2671575A1 (en) 2012-06-04 2013-12-11 Universität Regensburg Ras inhibitors
JP2017131851A (ja) 2016-01-29 2017-08-03 日本特殊陶業株式会社 マイクロ波加熱用触媒材料、マイクロ波加熱用触媒体、及び、その製造方法

Also Published As

Publication number Publication date
EP2474524A2 (en) 2012-07-11
WO2008083056A2 (en) 2008-07-10
WO2008083056A3 (en) 2009-04-30
US20100221182A1 (en) 2010-09-02
MX2009007018A (es) 2009-11-26
TW201628660A (zh) 2016-08-16
KR20140140134A (ko) 2014-12-08
BRPI0722082A8 (pt) 2018-03-13
CA2673853C (en) 2017-10-31
AU2007339954B2 (en) 2013-06-20
TWI549692B (zh) 2016-09-21
MX367292B (es) 2019-08-13
EP2474524A3 (en) 2012-07-18
ES2805286T3 (es) 2021-02-11
KR20090097946A (ko) 2009-09-16
KR20170102580A (ko) 2017-09-11
DK2114873T3 (da) 2013-05-13
ES2804801T3 (es) 2021-02-09
JP2010514786A (ja) 2010-05-06
US20180339070A1 (en) 2018-11-29
US20220288243A1 (en) 2022-09-15
CN101687780B (zh) 2016-01-20
TWI618544B (zh) 2018-03-21
IL224396B (en) 2018-04-30
CO6231002A2 (es) 2010-12-20
JP6021860B2 (ja) 2016-11-09
CN110003079A (zh) 2019-07-12
US8491868B2 (en) 2013-07-23
TW200848078A (en) 2008-12-16
DK2474525T3 (da) 2020-07-13
JP2016183164A (ja) 2016-10-20
HK1138260A1 (en) 2010-08-20
EP2474525B1 (en) 2020-04-15
US11241509B2 (en) 2022-02-08
KR101810348B1 (ko) 2017-12-18
SG177918A1 (en) 2012-02-28
CA2673853A1 (en) 2008-07-10
JP2014237679A (ja) 2014-12-18
US10010631B2 (en) 2018-07-03
EP2474525A2 (en) 2012-07-11
ES2405655T3 (es) 2013-05-31
CN101687780A (zh) 2010-03-31
EP2114873B1 (en) 2013-02-20
BRPI0722082A2 (pt) 2014-04-01
DK2474523T3 (da) 2020-07-13
JP5656408B2 (ja) 2015-01-21
KR101718160B1 (ko) 2017-03-20
IL253885A0 (en) 2017-10-31
AU2007339954A1 (en) 2008-07-10
US20140030189A1 (en) 2014-01-30
EP2474526A3 (en) 2012-07-25
CN105622463A (zh) 2016-06-01
EP2474525A3 (en) 2012-07-25
RU2506256C2 (ru) 2014-02-10
EP2114873A2 (en) 2009-11-11
IL199563A (en) 2017-08-31
EP2474523B1 (en) 2020-04-08
EP2474523A2 (en) 2012-07-11
CA2984226C (en) 2021-02-23
ZA200904828B (en) 2014-12-23
RU2009128591A (ru) 2011-02-10
PT2114873E (pt) 2013-05-06
EP2474523A3 (en) 2012-07-18
CA2984226A1 (en) 2008-07-10
CN105622463B (zh) 2019-02-22
KR20160049044A (ko) 2016-05-04
EP2474526A2 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
PL2114873T3 (pl) N-[3-Bromo-4-(3-[18F]fluoropropoksy)-benzylo]-guanidyna do obrazowania unerwienia serca
EP2220074A4 (en) 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
HK1159624A1 (en) Crystalline forms of (r) -5- [3-chloro-4-( 2, 3-dihydroxy-propoxy)-benz [z]ylidene]-2- ([z]-propylimino) -3-o-tolyl-thiazolidin-4-one (r)-5-[3--4-(23-)-[z]]-2-([z]-)-3- -4-
AP2008004580A0 (en) Herbicidal isoyazoline compounds
GB0614471D0 (en) Herbicidal Compounds
GB0624760D0 (en) Herbicidal compounds
HK1160139A1 (en) Biocidal boronophthalide compounds 2-[c]
BRPI0923176A2 (pt) salde hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3 trifluorometilbenzilóxi-imino)-etil]-2etil-benzil]-azetidina-3-carboxílio.
ZA200801351B (en) Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors
EP2165610A4 (en) AGENT FOR COMBATING ABDOMINAL TYMPANISM FOR RUMINANTS
HK1189591A1 (en) Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22-
IL199652A0 (en) 3-amino-1,2-benzisothiazole compounds for combating animal pest ii
ZA201100508B (en) Sulfoximinamide compounds for combating animal pests
ZA201100422B (en) 1,2-benzisothiazole compounds useful for combating animal pests
EP2046112A4 (en) CAROUSEL MELKING SYSTEM FOR ANIMALS
EP2001282A4 (en) ROTARY ROOM FOR ANIMAL TREATMENT
EP2024233A4 (en) STORAGE OF TWINE COILS FOR BOTTLEUMS
GB0612508D0 (en) Crystalline duloxetine hydrochloride
EP1874755A4 (en) BENZOTHIOPHENE-hydroxamic acid derivatives
PL2234595T3 (pl) Sposób zmniejszania tendencji soli glikopironiowej do agregacji podczas składowania
GB0700830D0 (en) Crystalline duloxetine hydrochloride
GB0612506D0 (en) Crystalline duloxetine hydrochloride
ZA201103269B (en) COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
ZA201000732B (en) 1-(azolin-2-yl)amino-1,2-diphenylethane compounds for combating animal pests
IL201511A0 (en) Substituted amino-thiourea compounds for combating animal pests